Experience

Davis Polk is advising iKang Healthcare Group, Inc. in connection with its acquisition for $41.20 per common share or $20.60 per American Depository Share by a consortium consisting of…

Davis Polk is advising Agilent Technologies, Inc. on its acquisition of privately held Advanced Analytical Technologies, Inc. in a $250 million cash transaction. The transaction is subject…

Davis Polk is advising Roche on its $1.9 billion acquisition of Flatiron Health, Inc. The transaction, which is expected to close in the first half of 2018, is subject to customary closing…

Davis Polk is advising Charles River Laboratories International, Inc. on its approximately $800 million acquisition of MPI Research Inc. The transaction, which is expected to close early in…

Davis Polk is advising J.P. Morgan Securities LLC as financial adviser to Varian Medical Systems, Inc. in connection with its approximately A$1.6 billion acquisition of Sirtex Medical…

Davis Polk is advising TiGenix in connection with its entry into an offer and support agreement with Takeda Pharmaceutical Company Limited, pursuant to which Takeda will make a public…

Davis Polk is advising Aetna on its approximately $77 billion acquisition by CVS Health. The transaction, which is expected to close in the second half of 2018, is subject to approval by…

Davis Polk is advising McKesson Corporation on its acquisition of RxCrossroads, a provider of tailored services to pharmaceutical and biotechnology manufacturers, from CVS Health…

Davis Polk is advising Advanced Accelerator Applications S.A. on its $3.9 billion acquisition by Novartis. Entry into the definitive agreement has been approved by the board of…

Davis Polk is advising PharMerica Corporation on its approximately $1.4 billion acquisition by a newly formed company controlled by KKR, with Walgreens Boots Alliance, Inc. as a minority…